Lara Meisner - 23 Jan 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Issuer symbol
VRDN
Transactions as of
23 Jan 2023
Net transactions value
-$103,331
Form type
4
Filing time
25 Jan 2023, 17:04:31 UTC
Previous filing
22 Dec 2022
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $114,482 +4,971 $23.03 4,971 23 Jan 2023 Direct
transaction VRDN Common Stock Options Exercise $26,208 +1,872 +38% $14.00 6,843 23 Jan 2023 Direct
transaction VRDN Common Stock Sale $244,021 -6,843 -100% $35.66 0 23 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -4,971 -11% $0.000000 39,750 23 Jan 2023 Common Stock 4,971 $23.03 Direct F2
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -1,872 -8.6% $0.000000 20,003 23 Jan 2023 Common Stock 1,872 $14.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F3 The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.